Islet cell transplant for brittle type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial studies whether transplanting insulin-producing islet cells can improve blood sugar control and reduce severe low blood sugar in people with “brittle” type 1 diabetes. It’s meant for adults with long-standing insulin dependence and troublesome, hard-to-control hypoglycemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 70, and able to give written consent
- Type 1 diabetes started before age 40, and you’ve needed insulin for at least 5 years
- Tests show low or absent insulin production (low C-peptide on a meal test) and you’ve had severe low blood sugar in the last year
- You must be doing intensive diabetes care (often checking sugars and using multiple daily insulin shots or a pump)
- You have documented low-blood-sugar unawareness or big blood sugar swings, based on screening questionnaires/tests
- You may not qualify if you have certain health issues (for example, BMI over 30, serious eye disease, kidney problems, active infections, or certain pregnancy plans)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether transplanting insulin-producing “islet” cells can better control blood sugar in people who have already received a kidney transplant. It’s mainly for adults with type 1 diabetes whose body is no longer making enough insulin, while they are on kidney-transplant medicines.
This trial tests a new treatment made from pig pancreatic cells (called OPF-310) that are placed under the skin to help control blood sugar in people with type 1 diabetes. It is for those whose diabetes is difficult to manage and who have dangerous low blood sugar episodes.
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
This trial looks at whether adding gastrin can improve outcomes after an islet cell transplant for people with type 1 diabetes. It may help some participants achieve better blood sugar control, but it also requires close follow-up and immune-suppressing medications to protect the new cells.
This study tests a one-time transplant of insulin-making cells from a donor to treat brittle type 1 diabetes—a condition where blood sugar swings wildly and dangerously low. The goal is to help people who still have severe low blood sugar episodes despite intensive insulin therapy.
This Phase 1 study tests a new immune-system strategy around islet transplantation (or donor bone marrow therapy) to improve control of type 1 diabetes and reduce dangerous low blood sugar. It mainly aims to see if the approach is safe and helpful in people with long-standing, difficult-to-manage diabetes.
Hear when a new Diabetes Mellitus, Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.